Health Canada approved Lupin Limited’s Rymti, the third etanercept biosimilar to be granted regulatory approval in the country. Meanwhile, Prestige Biopharma announced that it withdrew its European application for its trastuzumab biosimilar.
Outside of the United States, 2 companies shared news regarding the progress, or lack thereof, of their respective biosimilars, with 1 announcing an approval and another experiencing a setback.
Canadian Approval of Etanercept Biosimilar
Health Canada has approved Rymti, an etanercept biosimilar developed by Lupin Limited, for use in patients with rheumatic conditions across Canada. The announcement from Lupin Limited marked the third biosimilar referencing blockbuster drug Enbrel to be approved in the country.
Etanercept is an injectable tumor necrosis factor inhibitor used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis in adults and children.
“Lupin is committed to enhancing patient access to high-quality, life-enhancing biosimilars…. The approval for Rymti in Canada is a key milestone in our endeavors to improving access to medicines. It underscores the scientific success of Lupin’s biosimilar programs and our commitment to advancing healthcare through innovation,” said Cyrus Karkaria, PhD, president of Lupin Limited’s biotech division.
Rymti follows in the footsteps of Brenzys and Erelzi, which were approved in August 2016 and April 2017, respectively. Additionally, there are 3 etanercept biosimilars approved in the European Union, 2 in the United States, and 5 in Brazil.
Prestige Biopharma Pulls European Application for Tuznue
Singapore-based Prestige Biopharma announced that it has withdrawn its application for marketing authorization for its trastuzumab biosimilar (Tuznue; HD201) that was submitted to the European Medicines Agency.
In May 2022, Prestige asked for their marketing authorization application (MAA) to be re-examined for Tuznue after it received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).
Despite its clinical trial data showing comparability and biosimilarity between the biosimilar and reference product (Herceptin), the CHMP gave a negative opinion because there was “disparity in the range of acceptance for the criteria of analytical comparability between the clinical testing batch and commercial production batch of HD201.”
During the re-examination period, a newly assigned main rapporteur gave a positive opinion but it could not overturn the CHMP’s range of acceptance for the analytical comparability criteria. Prestige voluntarily withdrew its MAA and said that it plans to reapply to EMA with supplemented data through more clinical testing and analysis to meet CHMP’s criteria.
Currently, applications for HD201 are under review by Health Canada and the Korea Ministry of Food and Drug Safety. Prestige said that plans to submit a biologics license application for the biosimilar to the FDA by the end of 2022.
Trastuzumab is used in the treatment of human epidermal growth factor 2-positive breast cancer and metastatic gastric cancer. As of September 2022, there are 6 EMA-authorized trastuzumab biosimilars (Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac).
Prestige’s internal and external expert advisory board panel commented, “The company’s confidence is based on the excellent pharmaceutical quality of HD201 proven through clinical studies and multiple analysis. Through the re-examination, we received positive opinion by the main rapporteur, which is encouraging. We will do our best to obtain approval for HD201 in US and Europe without any doubt and provide patients with better access to treatments.”
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment
December 9th 2024The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.